

AMENDMENTS TO THE CLAIMS

1-17. (canceled)

18. (currently amended) A method of producing activated T cells directed toward hepsin, comprising the steps of:

exposing dendritic cells to a ~~hepsin-protein~~ hepsin fragment having the sequence of SEQ ID NO. 28 or 148, thereby producing activated dendritic cells;

exposing said activated dendritic cells to T cells, wherein said activated dendritic cells would present said hepsin fragment to said T cells, thereby producing activated T cells directed toward said ~~hepsin-protein or~~ hepsin fragment.

19-21. (canceled)

22. (previously presented) The method of claim 18, wherein said dendritic cells, which are isolated from an individual prior to said exposure to said hepsin fragment, are reintroduced

into said individual subsequent to said exposure to said hepsin fragment.

23-31. (canceled)

AMENDMENTS TO THE SPECIFICATION

Please amend the Cross-Reference to Related Applications on page 1 as follows:

This is a continuation-in-part application which claims the benefit of priority under 35 USC §120 of USSN 09/861,966, filed May 21, 2001, now U.S. Patent No. 6,518,028, which is a divisional application of US Pat. No. 6,268,165, which claims the benefit of priority under 35 USC §120 of USSN 09/039,211, filed March 14, 1998, which claims benefit of provisional patent application USSN 60/041,404, filed March 19, 1997, now abandoned.